|
|
|
|
|
|
By GlobalData | Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections. | |
|
|
| Reducing The Time And Cost Of Robust Analytical Method Development | Application Note | By Patrick Kellish, Danielle Kling, Richard Smindak, et al., Kincell Bio | Design-of-experiment methodology accelerates cell therapy assay development, reducing costs and timelines while improving assay robustness, regulatory readiness, and data-driven decision-making. |
|
|
| Unlocking The Economics Of AAV Gene Therapy | Article | Touchlight | Optimizing DNA inputs is key to scaling AAV therapies; cell-free enzymatic methods can cut costs up to 22%, saving millions annually at commercial scale. |
|
|
| De-Risk Nucleic Acid Therapeutics Through Strategic Outsourcing | White Paper | By Andrea Hawe and Anna Gebhardt, Coriolis Pharma | Bringing a nucleic acid therapy to market requires specialized formulation and development knowledge. Innovators need rigorous analytical and formulation strategies to achieve stability and quality. |
|
|
|
| Efficient Late-Stage Development Of Biologics | White Paper | ProBio | Reducing biologics manufacturing costs requires strategic late-stage process development, yield optimization, scale-up, and raw material substitution—all while maintaining product quality. |
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
